The Supreme Court Draws a Line
A Russian company has protected its right to develop and market a generic drug.
A conflict over public registration of Nexler ® (INN Fingolimod) by BioIntegrator) is resolved. The Supreme Court of the Russian Federation has confirmed the legitimacy of state registration of the above drug.
It should be recalled, that a year and a half ago the Swiss “Novartis Pharma AG” claimed that marketing authorization of the first Russian oral drug Nexler® for multiple sclerosis be recalled. The company alleged that the application for marketing authorization contained information received in the course of development of Gilenia®.
Patients with multiple sclerosis were hostages of litigation (the case was considered for more than a year), as they had no access to effective modern local drug with full cycle production, including substance, localized in Russia.
Now the situation will change. The Supreme Court of the Russian Federation, having considered the cassation appeal, has confirmed the legitimacy of earlier decisions by the Moscow Arbitrary Court and Intellectual Property Court in favor of BioIntegrator.
BioIntegrator, a ChemRar company, has become the first Russian pharmaceutical company to struggle against attempts by international companies to interpret the current legislation differently.